Nothing Special   »   [go: up one dir, main page]

Jakab et al., 2004 - Google Patents

Role of Posttransplant Alloantibodies in Patient Survival After Liver Transplantation

Jakab et al., 2004

Document ID
10996707424190769786
Author
Jakab J
Fehervari I
Borka P
Tamas R
Soos I
Jaray J
Publication year
Publication venue
Transplantation

External Links

Snippet

Aims: The anemia without bleeding is a frequent complication in patients after liver transplantation. In most cases underlying hemolysis caused by posttransplant alloantibodies is responsible. We have investigated the role of this complication in patient survival …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Brasile et al. Potential of repairing ischemically damaged kidneys ex vivo
El Haggan et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine
Lodge et al. EFFICACY AND SAFETY OF RECOMBINANT FACTOR VIIa (rFVIIa) ON TRANSFUSION REDUCTION IN ORTHOTOPIC LIVER TRANSPLANTATION (OLT)–A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Budde et al. Safety and efficacy of reduced or full dose of cyclosporine (neoral®) in combination with mycophenolatesodium (myfortic®), basiliximab (simulect®), and steroids in de novo kidney transplant recipients
Dean et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus
Laftavi et al. The significance of protocol biopsy in immunominimization protocol: A prospective study of steroid withdrawal
Young et al. Transient telomerase expression in normal somatic cells leads to telomere extension and increased proliferation in the absence of malignant transformation
Jakab et al. Role of Posttransplant Alloantibodies in Patient Survival After Liver Transplantation
Lewis et al. PROSPECTIVE RANDOMISED TRIAL OF LAPAROSCOPIC VERSUS OPEN LIVE DONOR NEPHRECTOMY: A COMPARISON OF POST-OPERATIVE RESPIRATORY FUNCTION
Charpentier et al. CO-STIMULATION BLOCKADE WITH LEA29Y IN RENAL TRANSPLANT: IMPROVED RENAL FUNCTION AND CV/METABOLIC PROFILE AT 6 MONTHS COMPARED WITH CYCLOSPORINE
Nath et al. Invasive Fungal Infections in Pancreas Transplant Recipients Receiving Alemtuzumab
Zhai et al. The Tlr4 Signaling Pathway Links Innate and Adaptive Immunity in Liver Ischemia and Reperfusion Injury
Osman et al. ROUTINE INSERTION OF URETERIC STENT IN LIVE-DONOR RENAL TRANSPLANTATION; IS IT WORTHWHILE?
Tanabe et al. Excellent renal function obtained by retroperitoneoscopic live donor nephrectomy under low CO2 gas pressure
Herrero-Fresneda et al. Gene therapy with hepatocyte growth factor attenuates the progression of chronic allograft nephropathy
De Feo et al. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors
Cortesini et al. Allospecific T regulatory and T suppressor cells in transplantation
Lee et al. ACHIEVING CONSISTENT MULTILINEAGE CHIMERISM AND IN VIVO KIDNEY ALLOGRAFT TOLERANCE IN A PORCINE MODEL OF IN UTERO BONE MARROW TRANSPLANTATION
Minguela et al. ANALYSIS OF CD95 AND CD28 EXPRESSION ON PERIPHERAL BLOOD T CELLS: A CLUE TO DIFFERENTIATE ACUTE REJECTION FROM HBV AND/OR HCV LIVER GRAFT RE-INFECTION.
Kappel et al. GENETIC DETECTION OF LYMPH NODE MICROMETASTASIS AS A SELECTION CRITERION FOR LIVER TRANSPLANTATION IN PATIENTS WITH LIVER METASTASIS FROM COLORECTAL CANCER.
Tchervenkov et al. Cadaveric renal transplantation and expanded criteria donors: Should we reassess their use?
Grandtnerova et al. CREATININE CLEARANCE AFTER KIDNEY TRANSPLANTATION-WHICH METHOD DO WE TRUST?
J Schulte Esch et al. PLATELET ACTIVATION MARKERS AND PROCOAGULANT PHENOTYPE OF MONOCYTES DO CORRELATE WITH MARKERS OF REPERFUSION INJURY FOLLOWING REPERFUSION AFTER ORTHOTOPIC LIVER TRANSPLANTATION
Lee et al. ACHIEVEMENT OF CONSISTENT STABLE MULTILINEAGE CHIMERISM IN A PRE-CLINICAL LARGE ANIMAL MODEL OF IN UTERO BONE MARROW TRANSPLANTATION
Challacombe et al. TRANSATLANTIC TELEMENTORING TO ENABLE LAPAROSCOPIC LIVE DONOR NEPHRECTOMY